European Heart Journal Advance Access published online on July 21, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi410
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiovascular Medicine, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, UK
* To whom correspondence should be addressed. Aims To define the N-terminal pro-brain natriuretic peptide (NTpBNP) normal range, assessing its cardiovascular screening characteristics in general population and higher risk subjects. Methods and results A total of 2320 subjects (1392 general population and 928 high-risk) Conclusion Normal NTpBNP levels should be stratified by age and gender. Normal NTpBNP levels give high NPV in excluding significant cardiovascular disease. Most subjects with raised NTpBNP levels and almost all subjects with NTpBNP levels over four times the normal have significant cardiovascular disease.
Received October 17, 2004
Revised April 30, 2005
Accepted June 16, 2005
Clinical research
What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?
2 Department of Chemical Pathology, St George's Hospital, London, UK
Roxy Senior, E-mail: roxy.senior{at}virgin.net
Abstract 
45 years old, selected randomly from seven community practices, were invited to undergo clinical assessment and echocardiography and to assess NTpBNP serum levels. Of these, 1205 attended. The NTpBNP normal range was calculated and its cardiovascular screening characteristics were assessed. Age (P < 0.0001) and female gender (P < 0.0001) independently predicted NTpBNP levels in normal subjects. In the general population, age- and gender-stratified normal NTpBNP levels gave a negative-predictive value (NPV) of 99% in excluding left ventricular systolic dysfunction, atrial fibrillation, and valvular heart disease, and a positive predictive value of 56% in detecting any cardiovascular disease assessed. In high-risk subjects, these values were 98 and 62%, respectively. Ninety-five per cent of subjects with NTpBNP levels over four times the normal had significant cardiovascular disease with the others having renal dysfunction.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Vaes, W. de Ruijter, J. Gussekloo, and J. Degryse The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review Age Ageing, November 1, 2009; 38(6): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Massie, P. E. Carson, J. J. McMurray, M. Komajda, R. McKelvie, M. R. Zile, S. Anderson, M. Donovan, E. Iverson, C. Staiger, et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction N. Engl. J. Med., December 4, 2008; 359(23): 2456 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Gabriel, A J Kerr, V Sharma, I S L Zeng, and R A H Stewart B-type natriuretic peptide and left ventricular dysfunction on exercise echocardiography in patients with chronic aortic regurgitation Heart, July 1, 2008; 94(7): 897 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Della Corte, G. Salerno, E. Chiosi, D. Iarussi, G. Santarpino, M. Miraglia, S. Naviglio, and M. De Feo Preoperative, postoperative and 1-year follow-up N-terminal pro-B-type natriuretic peptide levels in severe chronic aortic regurgitation: correlations with echocardiographic findings Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos and D. M. Lloyd-Jones Multiple Biomarker Panels for Cardiovascular Risk Assessment N. Engl. J. Med., May 15, 2008; 358(20): 2172 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
M. Tretjak and M. Kozelj Tissue Doppler annular velocities, NT-proBNP and exercise capacity in healthy elderly Age Ageing, May 1, 2008; 37(3): 336 - 339. [Full Text] [PDF]
|
|
|
|
 |
|
 O.W. Nielsen, P.J. Cowburn, A. Sajadieh, J.J. Morton, H. Dargie, and T. McDonagh Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care Eur J Heart Fail, December 1, 2007; 9(12): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Goode, A. L. Clark, J. A. Bristow, K. B. Sykes, and J. G.F. Cleland Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: A cost-benefit analysis Eur J Heart Fail, December 1, 2007; 9(12): 1186 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.P. Schoen, T. Zimmermann, T. Kittner, M.U. Braun, J. Fuhrmann, A. Schmeisser, and R.H. Strasser NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects Eur J Heart Fail, June 1, 2007; 9(6-7): 660 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Turley, A P Roberts, A Davies, N Rowell, J Drury, R H Smith, A Shyam-Sundar, and M J Stewart NT-proBNP and the diagnosis of left ventricular systolic dysfunction within two acute NHS trust catchment areas: the initial Teesside experience Postgrad. Med. J., March 1, 2007; 83(977): 206 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Goetze, R. Mogelvang, L. Maage, H. Scharling, P. Schnohr, P. Sogaard, J. F. Rehfeld, and J. S. Jensen Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction Eur. Heart J., December 2, 2006; 27(24): 3004 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wolber and M. Maeder Normal range of N-terminal pro-brain natriuretic peptide: a note of caution Eur. Heart J., March 1, 2006; 27(5): 622 - 622. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Markham and J. A. de Lemos Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humours Eur. Heart J., November 1, 2005; 26(21): 2220 - 2221. [Full Text] [PDF]
|
|